• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

Merck finally gets FDA nod to relaunch HIV trials, but drops preventive therapy plans

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Sep 20, 2022 at 10:32: AM
via A path forward for Merck & Co.’s struggling HIV strategy has opened up, with the FDA releasing a nine-month clinical hold on trials of the Big Pharma’s drug islatravir as long as low doses are used. However, the company has also decided to ditch its plans to explore the drug as a preventive treatment.

article source
 




Top Bottom
Back
Quote